An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Cabotegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms ImPrepCab; The ImPrEP CAB Study
Most Recent Events
- 12 Mar 2025 According to a ViiV Healthcare media release, data from this study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2025),
- 12 Mar 2025 Results presented in the ViiV Healthcare Media Release
- 06 Mar 2024 Results assessing the accuracy of indirect PrEP adherence measures with drug concentrations in dried blood spots (DBS) among YMSM and TGW enrolled in the ImPrEP study, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.